Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Respiratory Medicine

• Publication date

  2016-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.rmed.2016.05.007PMID 27296819
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Summary of product characteristics

  2016cited by this paper
• Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy.

  2015cited by this paper
• Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)

  2015cited by this paper
• Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies

  2014cited by this paper
• Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study

  2014cited by this paper
• Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study

  2014cited by this paper
• Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study

  2014cited by this paper
• Minimal clinically important differences in pharmacological trials.

  2014cited by this paper
• Safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three phase III studies

  2014cited by this paper
• ACCORD COPD II: A Randomized Clinical Trial to Evaluate the 12-Week Efficacy and Safety of Twice-Daily Aclidinium Bromide in Chronic Obstructive Pulmonary Disease Patients

  2013cited by this paper
• Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study

  2012cited by this paper
• Efficacy and Safety of a 12-week Treatment with Twice-daily Aclidinium Bromide in COPD Patients (ACCORD COPD I)

  2012cited by this paper
• Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study

  2012cited by this paper
• Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients.

  2011cited by this paper
• A one-year trial of tiotropium Respimat plus usual therapy in COPD patients.

  2010cited by this paper
• Formoterol in the management of chronic obstructive pulmonary disease

  2008cited by this paper
• Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease.

  2008cited by this paper
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

  2007cited by this paper
• Reducing cholinergic constriction: the major reversible mechanism in COPD

  2006cited by this paper
• Distribution of receptor targets in the lung.

  2004cited by this paper
• Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels

  1994cited by this paper
• In vitro responsiveness of human asthmatic bronchus to carbachol, histamine, beta-adrenoceptor agonists and theophylline.

  1986cited by this paper

• Incremental long-term benefit of drug therapies for chronic obstructive pulmonary disease in quality of life but not mortality: a network meta-analysis

  2024cites this paper
• Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials

  2023cites this paper
• Bronchodilator therapy in patients with chronic obstructive pulmonary disease: what should be considered in clinical practice when choosing a dosing regimen?

  2023cites this paper
• Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis

  2022cites this paper
• Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis

  2022cites this paper
• Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD

  2022cites this paper
• Evidence-based management approaches for patients with severe chronic obstructive pulmonary disease (COPD): A practice review

  2022cites this paper
• Future concepts in bronchodilation for COPD: dual- versus monotherapy

  2021cites this paper
• Comparison of efficacy and side effects of fixed-dose combination of Aclidinium/Formoterol and Monotherapy of Aclidinium or Formoterol in COPD: A meta-analysis.

  2021cites this paper
• Is the use of two versus one long-acting bronchodilator by patients with COPD associated with a higher risk of acute coronary syndrome in real-world clinical practice?

  2021cites this paper
• Dual LABA/LAMA Therapy versus LABA or LAMA Monotherapy for COPD: A Systematic Review and Meta-analysis in Support of the American Thoracic Society Clinical Practice Guideline.

  2020cites this paper
• Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO®/DYNAGITO® Trials

  2020cites this paper
• Aclidinium bromide and formoterol fumarate for the maintenance treatment of chronic obstructive pulmonary disease

  2020cites this paper
• Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline

  2020cites this paper
• New opportunities of dual bronchodilation therapy for patients with chronic obstructive pulmonary disease.

  2019cites this paper
• Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base

  2019cites this paper
• How to interpret the results of comparative drug tests? Statistical analysis methods: standardized SMD mean difference and mean difference calculated by the LSMD least squares method

  2019cites this paper
• Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease

  2019cites this paper
• aMPlIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD

  2019cites this paper
• AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD

  2019cites this paper
• The discovery and development of aclidinium bromide for the treatment of chronic obstructive pulmonary disease

  2018cites this paper
• Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).

  2018cites this paper
• Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.

  2018cites this paper
• Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.

  2018cites this paper
• The safety of dual bronchodilation on cardiovascular serious adverse events in COPD

  2018cites this paper
• LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

  2018cites this paper
• LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

  2018cites this paper
• Safety of inhaled long-acting anti-muscarinic agents in COPD

  2017cites this paper
• A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease.

  2017cites this paper
• The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis

  2017influential citation
• Dual bronchodilator therapy for chronic obstructive pulmonary disease: evidence for the efficacy and Safety of fixed dose combination treatments in the setting of recent guideline updates

  2017cites this paper
• Multiple Ansätze wider die Progression

  2017cites this paper
• The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis

  2017cites this paper
• Dual bronchodilation in COPD: lung function and patient-reported outcomes – a review

  2016cites this paper
• Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease

  2015cites this paper